Platinum-Based Drugs in Cancer Therapy

ISBN-13: 9780896035997 / Angielski / Twarda / 2000 / 341 str.

Lloyd R. Kelland; Nicholas Farrell

Opis

Leading international experts comprehensively review all aspects of platinum anticancer drugs and their current use in treatment, as well as examining their future therapeutic prospects. Writing from a variety of disciplines, these authorities discuss the chemistry of cisplatin in aqueous solution, the molecular interaction of platinum drugs with DNA, and such exciting new areas as DNA mismatch repair and replicative bypass, apoptosis, and the transport of platinum drugs into tumor cells. The emergent platinum drugs of the future-orally active agents, the sterically hindered ZD0473, and the polynuclear charged platinum BBR3464-are also fully considered. Timely and interdisciplinary, Platinum-Based Drugs in Cancer Therapy offers cancer therapeutics specialists an illuminating survey of every aspect of platinum drugs from mechanisms of action to toxicology, tumor resistance, and new analogs.

Recenzje

This volume of the Cancer Drug Discovery and Development series provides comprehensive coverage of some of the basic science associated with cisplatin, its interaction with DNA and how recognitions and processing of platinum-DNA adducts may be associated with tumour response or resistance. ...Bringing together the most recent research in the area of platinum drugs...The editors of this book have produced a collection of articles which will be of interest to those who need an introduction to the field of platinum drugs. For anyone already familiar with the field, the chapters on the newer analogues and on some of the more recent basic molecular pharmacology issues will provide a useful update. -The Lancet

"The great attention is also paid to all toxicological aspects of platinum drugs from both clinical and regulatory perspective.... The Platinum-based Drugs in Cancer Therapy appears to be a comprehensive book useful for scientist, medical oncologist and pharmacist seeking answer on specific questions concerning preclinical and clinical data of platinum drugs."-Neoplasma

"The strength of the text lies in the diversity of topics that are covered in such a succinct fashion. Clinicians will benefit from the earlier focus on basic chemistry and biochemistry, while the bench scientist will better appreciate the practicalities of using these compounds from the lucid experiences of the clinical case studies."-Journal of Medicinal Chemistry

"This is a useful reference book for scientists and practitioners who have a focus or interest in the chemistry and biochemistry of the platinum compounds. Oncologists will find it helpful for its summary of applications of cisplatin and carboplatin, especially in combination with paclitaxel."--Oncology Journal, November, 2000

"...the book should find its place in the library of many laboratories involved mainly in preclinical oncological research."-Annals of Oncology

"This new book by Kelland and Farrell is a well-constructed and authoritative account of current knowledge concerning the pharmacology and clinical application of platinum anticancer drugs. It is well illustrated with clear diagrams and appropriate data. ...Not only do platinum agents remain a key component of current cancer therapy for the majority of common solid tumours but recent advances have demonstrated the scope for expansion of the clinical spectrum of activity, the ability to overcome resistance, and the potential introduction of oral delivery." - Clinical Oncology

Spis treści

Part I: Platinum Chemistry. The Chemistry of Cisplatin in Aqueous Solution, Susan J. Berners-Price and Trevor G. Appleton. Chemistry and Structural Biology of 1,2-Interstrand Adducts of Cisplatin, Viktor Brabec. Transplatin-Modified Oligonucleotides as Potential Antitumor Drugs, Marc Leng, Annie Schwartz, and Marie-Josephe Giraud-Panis. Part II: Platinum Biochemistry. Cisplatin Accumulation, Paul A. Andrews. Cisplatin Resistance in Ovarian Cancer: Mismatch Repair and Engagement of Apoptosis, Robert Brown. DNA Adduct Tolerance and Bypass, Stephen G. Chaney and Alexandra Vaisman. How Does Cisplatin Kill Cells? Daniel Fink and Stephen B. Howell. Part III: Clinical Antitumor Activity and Toxicology of Platinum Drugs. Clinical Experience with Cisplatin and Carboplatin, M. S. Highley and A. H. Calvert. Clinical Experience: Platinum and Taxanes, Michelle Vaughan, Francisco Sapunar, and Martin Gore. Clinical Experience: DACH-Based Platinum Drugs, Peter J. O'Dwyer, James P. Stevenson, and Steven W. Johnson. Clinical Toxicology of Platinum-Based Cancer Chemotherapeutic Agents, Mark J. McKeage. Toxicology and Regulatory Aspects of Platinum Drugs, Diana L. Clark, Paul A. Andrews, D. D. Smith, Joseph J. DeGeorge, Robert L. Justice, and Julie G. Beitz. Part IV: New Platinum Drugs of the Future. New Platinum Drugs: The Pathway to Oral Therapy, Lloyd R. Kelland. Polynuclear Charged Platinum Compounds as a New Class of Anticancer Agents: Toward a New Paradigm, Nicholas Farrell. Index.

Blurb

In Platinum-Based Drugs in Cancer Therapy, leading international experts comprehensively review all aspects of platinum anticancer drugs and their current use in treatment, as well as examining their future therapeutic prospects. Writing from a variety of disciplines, these authorities discuss the chemistry of cisplatin in aqueous solution, the molecular interaction of platinum drugs with DNA, and such exciting new areas as DNA mismatch repair, replicative bypass, apoptosis, and the transport of platinum drugs into tumor cells. The antitumor activity and toxicology of platinum-based drugs is also addressed in a thorough discussion of the clinical experience with cisplatin and carboplatin, including their promising recent combinations with taxanes and oxaliplatin. The emergent platinum drugs of the future-orally active agents, the sterically hindered ZD0473, and the polynuclear charged platinum BBR3464-are also fully considered.
Timely and interdisciplinary, Platinum-Based Drugs in Cancer Therapy offers cancer therapeutics specialists an illuminating survey of every aspect of platinum drugs from mechanisms of action to toxicology, tumor resistance, and new analogs. This important book captures the essence of the fresh clinical possibilities now strongly emerging thirty years after cisplatin's discovery.